Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;38(6):1707-1710.
doi: 10.1007/s40620-025-02305-6. Epub 2025 May 19.

Contributing factors and clinical usefulness of spot urine glucose-to-creatinine ratio by sodium glucose cotransporter 2 inhibitors: a cross-sectional study

Kojiro Nagai  1 , Keisuke Morita  2 , Ken Matsuo  2 , Satoshi Tanaka  2
Affiliations

Contributing factors and clinical usefulness of spot urine glucose-to-creatinine ratio by sodium glucose cotransporter 2 inhibitors: a cross-sectional study

Kojiro Nagai et al. J Nephrol. 2025 Jul.
No abstract available

Keywords: Chronic kidney disease; Diabetes; Sodium glucose cotransporter 2 inhibitor; Urinary glucose excretion.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The author reports no conflicts of interest. Ethical approval: This study was performed in compliance with the Declaration of Helsinki. This study was approved by the Research Ethics Committee of Shizuoka General Hospital (approval number: SGHIRB#2022030). Human and animal rights: This manuscript does not include animal experimental data. Consent to participate: Informed consent to participate was obtained in an opt-out fashion using a poster posted at outpatient department, and the hospital’s website.

Figures

Fig. 1
Fig. 1
a Correlations between possible factors related to the spot urine glucose-to-creatinine ratio in all patients (n = 226). Alb albumin. eGF, eGFRcre creatinine-based estimated glomerular filtration rate. Glu glucose. HbA HbA1c. Pota potassium. Chlo chloride. Calc calcium. FE, FEUN fractional excretion of urea nitrogen. β2M, β2MG/Cre β2-microglobulin (creatinine corrected). α1M, α1MG/Cre α1-microglobulin (creatinine corrected). UG, UG/Cre spot urine glucose-to-creatinine ratio. b Significant independent factors for spot urine glucose-to-creatinine ratio in all patients (n = 226). eGFRcre creatinine-based estimated glomerular filtration rate. FEUN fractional excretion of urea nitrogen. β2MG/Cre β2-microglobulin (creatinine corrected). α1MG/Cre α1-microglobulin (creatinine corrected). SE standard error. c Scatter plots of 24 h urine and spot urine glucose-to-creatinine ratio (n = 39). d Scatter plots of 24 h urine glucose-to-creatinine ratio and estimated GFR (n = 39). eGFRcre: creatinine-based estimated glomerular filtration rate. e Scatter plots of spot urine glucose-to-creatinine ratio and estimated GFR (n = 226). eGFRcre creatinine-based estimated glomerular filtration rate
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y (2016) Interaction of the sodium/Glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 358:94–102. 10.1124/jpet.116.232025 - PubMed
    1. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446. 10.1056/NEJMoa2024816 - PubMed
    1. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW, CREDENCE Trial Investigators (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306. 10.1056/NEJMoa1811744 - PubMed
    1. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388(117):127. 10.1056/NEJMoa2204233
    1. Bakris G, Oshima M, Mahaffey KW, Agarwal R, Cannon CP, Capuano G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Neal B, Oh R, Pollock C, Rosenthal N, Wheeler DC, Zhang H, Zinman B, Jardine MJ, Perkovic V (2020) Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m. Clin J Am Soc Nephrol 15:1705–1714. 10.2215/CJN.10140620 - PMC - PubMed

LinkOut - more resources